Mr Adam Frampton

Qualifications

BSc (Hons), MSc, PhD, MBBS, MRCSEd, FRCS (Gen Surg), FRSB, DipMedTox

GMC number: 6078003

Practicing since: 2003

Specialties

General Surgery

Consultation times

  • Fridays 13:30–18:30
  • Overview
Enquire now

Or call us on

01483 555914

About

Mr Adam Frampton is a Consultant General and Hepato-Pancreato-Biliary (HPB) Surgeon based in Guildford and London. He is a specialist in treating hernias and gallstones, as well as benign and cancerous disorders of the liver, pancreas and biliary-tract.

Mr Frampton's interests include minimally invasive surgery, acute/chronic pancreatitis, complex gallstone disease, bile duct stones, pancreatic cysts, neuroendocrine tumours and abnormal liver function tests/jaundice.

He qualified from Imperial College London in 2003 and completed his specialist training on the South-West London rotation. He advanced his surgical skills training in laparoscopic/robotic HPB surgery at the Hammersmith and Royal Marsden Hospitals, and in liver transplantation at the Royal-Free Hospital, London.

Mr Frampton is a well recognised ‘surgical scientist’ and is an active researcher alongside his clinical practice. He was awarded a PhD from Imperial in 2013 for his work on pancreatic cancer. He was also awarded the distinguished Hunterian Professorship by the Royal College of Surgeons of England in 2018. He is currently the Vice Chancellor’s Fellow/Senior Lecturer in Surgical Oncology at the University of Surrey where he leads a laboratory group and supervises BSc, MD and PhD students.

His primary aim is to develop cutting-edge research, and translate findings into patient benefits, using an evidence-based approach.

Special interests

1. Removal of skin ‘lumps and bumps’ e.g. lipoma, sebaceous cysts, skin tags, abscess drainage

2. Gallstone disease:

  • Open/laparoscopic cholecystectomy (gallbladder removal) with on-table cholangiography
  • Open/laparoscopic common bile duct (CBD) exploration and clearance
  • Completion cholecystectomy (previously abandoned elsewhere)
  • Repair of bile duct injuries/biliary reconstruction.

3. Groin and abdominal wall hernia repair e.g. inguinal, femoral, umbilical, incisional, recurrent

4. Management of acute and chronic pancreatitis (multidisciplinary and multimodal approach)

5. Pancreatic pathology (benign/malignant) e.g. Pancreatic cancer, Pancreatic cystic lesions:

  • Open/laparoscopic distal pancreatectomy and splenectomy
  • Pancreaticoduodenectomy (Whipple's procedure/PPPD)
  • Total pancreatectomy and splenectomy
  • Central pancreatectomy.

6. Biliary and liver pathology (benign/malignant) e.g. gallbladder polyps, hepatocellular carcinoma, colorectal liver metastases, biliary-tract cancers (gallbladder, ampullary, cholangiocarcinoma), liver cysts, liver adenoma, focal nodular hyperplasia:

  • Open/laparoscopic liver resection (hepatectomy)

7. Splenectomy for haematological malignancies

8. Excisional biopsy, including groin and axillary lymph nodes

9. Diagnostic laparoscopy to investigate abdominal symptoms

10. Duodenal pathology e.g. gastrointestinal stromal tumours (GIST), duodenal adenoma/cancer

11. Management of neuroendocrine tumors (NET) such as small bowel/carcinoid and pancreatic, as well as metastatic disease to the liver.

Other interests

  • Robotic surgery
  • Multimodal treatment to increase the resectability of patients with advanced pancreatic cancer and colorectal liver metastases
  • Assessment of acute abdominal problems and emergency surgery (e.g. laparoscopic appendicectomy for appendicitis, abscess drainage, treatment of bowel obstruction/bowel perforation)
  • Surgical oncology

Personal interests

Mr Frampton enjoys spending time with his family and has 3 young children that keep him busy.

Languages spoken

English

Treatments and tests offered by Mr Adam Frampton at Nuffield Health

  • Gastroesophageal
  • Appendicectomy
  • Splenectomy
  • Gastrointestinal radiology
  • Excisional biopsy
  • CT scan (or CAT scan)
  • Umbilical hernia repair
  • Hernia repair
  • Excision of skin lesion
  • Liver function tests
  • Cholecystectomy (Gallbladder removal)
  • Skin surgery
  • Specialist abdominal radiology
  • Liver biopsy
  • MRI scan
  • Bilateral (inguinal) hernia repair
  • Abdominal adhesion surgery
  • Gastrointestinal tract
  • Hernia unilateral
  • Ultrasound
  • Bile duct resection
  • Laparoscopic cholecystectomy (gallbladder removal)

Locations Mr Adam Frampton works with

Related experience

Research

Mr Adam Frampton is one of the few 'surgical scientists' in HPB Surgery in the UK. He was awarded his PhD in Molecular Oncology in 2014 from Imperial College London on the complex gene interactions in pancreatic cancer. He ran a laboratory group at the Hammersmith Hospital, Imperial College from 2015 to 2021, prior to moving to Surrey.

He won the Moynihan Prize in May 2017 for his research, which is the most prestigious scientific award given by the Association of Surgeons of Great Britain and Ireland. He was elected as a Fellow of the Royal Society of Biology in July 2017 for his contributions to small-RNA and cancer biology. He was then awarded the distinguished Hunterian Professorship by the Royal College of Surgeons of England in May 2018.

He is currently the Vice Chancellor’s Fellow/Senior Lecturer in Surgical Oncology at the University of Surrey where he continues his laboratory research alongside his surgical practice. His research is focussed on:

  • Discovering molecular biomarkers for improving detection, prognostication, and stratification of patients with pancreatic, biliary-tract and liver cancers, and developing novel targets for anti-cancer therapy
  • Investigating the tumour microenvironment and microbiome in pancreatic cancer
  • Investigating mechanisms of metastasis (cancer spread) in pancreatic and colorectal cancers.

His studies are translational, and aim to develop clinical-useful biomarkers, which will clearly benefit patients and staff, as more accurate and efficient biomarkers will allow a more timely diagnosis and reduce the number of clinical investigations required. This in turn will also reduce the cost to the NHS.

These biomarkers have the potential to enhance decision making by stratifying patients and 'personalising therapy', which should improve outcomes (i.e. reduced complications, reduced mortality and improved survival).

He has published more than 120 research articles and has presented his findings nationally and internationally. He is an Editor for the journal Cancers and a peer reviewer for British Journal of Surgery, Gastroenterology, Scientific Reports, GUT, European Journal of Surgical Oncology, and Annals of Surgery.

Memberships

  • Fellow of the Royal College of Surgeons of England
  • Member of the Royal College of Surgeons of Edinburgh
  • Association of Surgeons of Great-Britain & Ireland (ASGBI)
  • European Pancreatic Club (EPC)
  • Association of Upper Gastro-intestinal Surgery of Great Britain & Ireland (AUGIS)
  • Pancreatic Society of Great Britain & Ireland (PSGBI)
  • International Hepato-Pancreato-Biliary Association (IHPBA)
  • Royal Society of Biology (RSB), London
  • Society for Surgery of the Alimentary Tract (SSAT), USA

Other posts held

  • Consultant General & Hepato-Pancreato-Biliary (HPB) Surgeon at the Royal Surrey NHS Foundation Trust
  • Vice Chancellor’s Fellow / Senior Lecturer in Surgical Oncology at the University of Surrey

Insurers Mr Adam Frampton works with

Mr Adam Frampton works with the following private medical insurance providers:

  • Aviva Health
  • AXA PPP Healthcare
  • AXA PPP International
  • Bupa
  • Bupa On Demand
  • Cigna
  • PHC
  • Vitality Health (Pru Health)
  • Westfield Health WPA

Declaration

Mr Adam Frampton does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Mr Adam Frampton does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Mr Adam Frampton does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.